GLS and neoplasm: In contrast, 2-DG as a glucose analog to block glucose metabolism, Etomoxir as a lipid β-oxidation inhibitor by selectively targeting CPT1, and BPTES as a glutamine metabolism inhibitor by selectively targeting glutaminase GLS1 exerted no significant effects on OPA1 expression in tumor spheres (Supplemental Figure 4A).